OPK Opko Health Inc

Wall Street Zen upgraded OPKO Health (NASDAQ:OPK) from a "sell" to a "hold" rating, contributing to a consensus "Hold" rating from analysts with a $2.28 price target. Insiders, notably CEO Phillip Frost, have significantly increased their stake, owning nearly 50% of the company after recent large purchases. Despite beating EPS estimates, OPKO Health missed revenue forecasts, with analysts predicting a negative EPS for the current fiscal year.

Wall Street Zen has downgraded OPKO Health (NASDAQ:OPK) from "hold" to "sell," while MarketBeat's consensus rating remains "Hold" with an average price target of $2.28. Despite the company being unprofitable, CEO Phillip Frost recently purchased 580,000 shares, bringing insider ownership to nearly 50%. The company reported Q3 EPS of $0.03, beating estimates, but revenue saw a 12.6% year-over-year decline.

Opko Health Inc.'s ModeX Therapeutics has entered into a license and collaboration agreement with Regeneron Pharmaceuticals. This agreement grants Regeneron an exclusive global license to develop and commercialize ModeX's preclinical, multispecific antibody programs for oncology and infectious diseases. ModeX will receive an upfront payment and is eligible for substantial milestone payments and royalties on future sales.

OPKO Health, Inc. (OPK) is positioned for growth, primarily driven by its leading renal product, RAYALDEE, and several strategic partnerships. Despite facing stiff competition and a reliance on RAYALDEE, the company has shown strong earnings performance, surpassing estimates in two of the last four quarters. Several clinical trials and collaborations further underpin its potential for future growth.

OPKO Health, Inc. (NASDAQ:OPK) has received a consensus "Hold" rating from seven brokerages, with an average one-year price target of $2.28. Insider activity shows CEO Phillip Frost purchased 580,000 shares, bringing total insider ownership to 49.69%. Despite beating earnings per share estimates, the company's revenue missed consensus, and it currently holds a negative net margin.

Geode Capital Management LLC significantly increased its holdings in OPKO Health, Inc. by 23.7% in Q2, bringing its total to over 10.4 million shares worth approximately $13.8 million. Concurrently, OPKO Health's CEO, Phillip Md Et Al Frost, also boosted his direct holdings by purchasing 580,000 shares. Despite the increased institutional and insider interest, analysts currently have a "Hold" rating on OPKO Health with an average price target of $2.28, noting the company remains unprofitable despite beating modest EPS expectations.